Kornimate/medical-research-clean huggingface dataset:
genetic liability in the brain morphology of attention deficit hyperactivity disorder

Conditions: Attention Deficit Hyperactivity Disorder

Summary: attention deficit hyperactivity disorder (adhd) is a heritable psychiatric disorder with onset in childhood. twin and adoption studies indicate that additive genetic factors explain up to 80% of the variance underlying susceptibility. the siblings of children with adhd have a three- to fivefold increased risk of having adhd compared to the siblings of healthy control subjects, and the risk is even greater for monozygotic twins with 50-80% concordance compared with up to 33% in dizygotic twins). as full siblings share on average 50% of their genes, even the unaffected siblings of children with adhd would be expected to share some of the genes involved in the disorder. the neuroanatomical substrate of adhd is becoming increasingly better defined by a growing body of evidence from imaging studies. evidence from neuroimaging studies suggests that this disorder is associated with reductions in brain volume up to 5% in these children. in this protocol we collected mri-scans from boys with adhd and their unaffected siblings, as well as control subjects. in addition, cheekswabs were later collected for dna analysis.


Eligibility criteria:
inclusion criteria: 1. age 7 - 18 years. inclusion criteria for patients 1. dsm-iv (apa, 1994) diagnosis of adhd (combined subtype), according to disc interview 2. scores in the clinical range on the child behavior checklist (cbcl) and teacher rating form (trf) 3. one brother who meets the inclusion criteria for siblings inclusion criteria for siblings 1. no dsm-iv (apa,1994) diagnosis for adhd or another disruptive disorder (odd or cd), according to disc interview 2. no scores in the clinical range on the child behavior checklist (cbcl) and teacher rating form (trf) inclusion criteria for controls 1. no dsm-iv (apa, 1994) diagnosis, according to disc interview 2. no scores in the clinical range on the child behavior checklist (cbcl) and teacher rating form (trf) exclusion criteria: 1. iq \< 70 2. illness of the cardiovascular, the endocrine, the pulmonal or the gastrointestinal system 3. the presence of metal objects in or around the body (pacemaker, dental braces)

Keywords: adhd; mri; genetics
aortic stiffness by cmr in aortic coarctation

Conditions: Aortic Coarctation

Summary: this study investigates the correlation between medium-term systemic blood pressure control and aortic stiffness index in adults following coarctation stenting, using cardiac magnetic resonance (cmr) imaging.

coarctation of the aorta (coa) is a common form of congenital heart disease with an incidence of 1 in 3000-4000 live births, characterized by the narrowing of the aorta, which leads to significant hemodynamic changes, including increased afterload, hypertension, and ultimately, adverse cardiovascular outcomes. despite successful surgical or interventional treatment to correct the anatomical defect, patients with coarctation of the aorta often continue to experience elevated systemic blood pressure and increased aortic stiffness, which are important predictors of long-term cardiovascular morbidity and mortality. stenting has emerged as a preferred interventional strategy for treating aortic coarctation in adults due to its less invasive nature and immediate efficacy in relieving aortic obstruction. however, the medium-term impact of stenting on aortic stiffness remains underexplored. understanding these changes is crucial for optimizing long-term management strategies and improving patient outcomes. cardiac magnetic resonance (cmr) imaging offers a non-invasive and highly accurate method for assessing aortic stiffness, providing detailed insights into the structural and functional properties of the aorta. the aortic stiffness index, derived from cmr measurements, serves as a valuable biomarker for vascular health and has been linked to systemic blood pressure levels. this study aims to investigate the correlation between medium-term systemic blood pressure control and aortic stiffness index in adults following coarctation stenting. by assessing patients pre- and post-stenting using cmr, we seek to determine whether improvements in aortic stiffness correspond with better blood pressure management over time. our findings could provide valuable insights into the benefits of stenting beyond immediate hemodynamic relief, highlighting its role in the long-term cardiovascular health of patients with aortic coarctation.

Eligibility criteria:
patient criteria inclusion criteria all patients with native or recurrent aortic coarctation between the age of 14 years and older. transcatheter systolic gradient ≥ 20 mm hg, body weight ≥ 20 kg, and normal lv ejection fraction (ef). exclusion criteria patients with obstructive lesion of lvot or aortic valve dysfunction greater than moderate (requiring surgical intervention). irregular cardiac rhythm. patients with other causes of secondary hypertension. contraindications to cmr: any contraindications to undergoing cmr, such as implanted metallic devices incompatible with mri, severe claustrophobia. unicuspid aortic valve associated complex congenital heart defects (aside from simple septal defects and patent ductus arteriosus) genetic syndromes connective tissue disorder history of surgery involving the aortic root or ascending aorta.

Keywords: aortic coarctation aortic stiffness cmr ambulatory blood pressure
articular cartilage resurfacing with mesenchymal stem cells in osteoarthritis of knee joint

Conditions: Osteoarthritis

Summary: knee osteoarthritis is the most common form of arthritis. treatments involve high costs in terms of social and economic, are palliative and do not contemplate healing by regenerative therapy. it has been shown recently, that mesenchymal stem cells (msc) can be expanded in vitro and may regenerate several damaged or injured tissues. in addition its has demonstrated that msc are able to modulate immune responses and to control inflammation through its action on t lymphocytes. preliminary studies in animal models, including one carried out in an equine by the investigators research group, confirms feasibility, safety and efficacy evidence proposed treatment protocol.this study is designed to evaluate therapeutic potential and safety of mesenchymal stem cells in improvement of osteoarthritis clinical manifestations.this study is designed to evaluate therapeutic potential and safety of mesenchymal stem cells in improvement of osteoarthritis clinical manifestations.

mesenchymal stem cells are pluripotent cells that can be obtained from various tissues .they have shown capabilities to differentiate into bone,cartilage,muscle,and adipose tissue, representing a new clinical strategy in regenerative medicine.an increasing number of reports have demonstrated effectiveness of percutaneous intra-articular infusion of mscs in arthritic disease. in this study we perform a single intra articular injection of cultured mesenchymal stem cells in patients suffering from osteoarthritis, with the aim to assess its clinical safety and efficacy.patients are assessed for response with mri, x-ray examination, womac osteoarthritis index,vas, and sf36 2,4,8 weeks and 6, and 12 months post infusion.

Eligibility criteria:
inclusion criteria: * female patients not pregnant or lactating. * patients with a history of corticosteroids or on active therapy, will only be eligible for enrollment if corticosteroid use is suspended for 1 month prior cell therapy * marcaine 0.75% و lidocaine 4% test performed to be assure the exact location of the pain is related to the knee. * diagnosis must be based on magnetic resonance imaging. * both genders * age:18-65 years exclusion criteria: * diagnosis of cancer,dm,cns disorder,thyroid disease or respiratory disease. * known allergic reaction to components of study treatment and/or study injection procedure * patients infected with hepatitis b,c or hiv.

Keywords: mesenchymal cells osteoarthritis intra articular injection
retrospective review of management of infective endocarditis

Conditions: Endocarditis

Summary: this is an analysis of the outcomes of patients having undergone surgical intervention for infective endocarditis.

this study will look at the presentations, epidemiology, risk factors, modalities of diagnosis; and the role of specific investigatory tools with surgical intervention and timimg of intervention in patients who underwent surgical treatment for infective endocarditis. morbidity and mortality post surgery and prognosis including long term outcome of our patients will be analyzed. special attention will be made to those patients with pre-operative neurological deficit.

Eligibility criteria:
inclusion criteria: * have undergone surgical treatment for infective endocarditis exclusion criteria: * less than 18 years old

Keywords: endocarditis neurological deficit
addressing psychosocial comorbidities in hiv treatment and prevention 2b

Conditions: Medication Adherence; Mental Health Issue

Summary: the purpose of this study is to learn about ways to better support people living with hiv with their hiv treatment and cope with mental health challenges and/or substance use concerns.


Eligibility criteria:
inclusion criteria: 1. age: 18 years or older 2. hiv positive 3. evidence of uncontrolled virus (e.g., \> 20 copies/ml) within the past 12 months as verified by medical record 4. group 1: (men who have sex with men (msm) who have used stimulants within the past 4 months (approximately 10 participants))or group 2: transgender women (approximately 10 participants) or group 3: emerging adults between the ages of 18 and 26 (inclusive; approximately 10 participants) exclusion criteria: 1. unable to provide informed consent due to severe mental or physical illness, cognitive impairment, or substance intoxication at the time of interview 2. active untreated, unstable, major mental illness (i.e., untreated psychosis or mania) that would interfere with study participation 3. opinion of the pi that the participant would be at risk for harm to self or others 4. currently receiving cbt for a psychiatric disorder, or received a course of cbt in the past year.

Keywords: hiv medication adherence mental health
multiple myeloma minimal residual disease

Conditions: Multiple Myeloma

Summary: three methods including flow cytometry, next generation sequencing and determination of circulating tumor cells will be performed at different time points in patients with previously undiagnosed multiple myeloma in order to determine the most sensitive method to detect residual disease


Eligibility criteria:
inclusion criteria: * ≥ 18 years * previously undiagnosed myeloma * eligible for high dose therapy and bone marrow transplantation * signed consent exclusion criteria: * ongoing therapy for another neoplasia * patients with other hematologic malignancies, * patients deprived of liberty for administrative or judicial reasons * previously treated for myeloma

Keywords: residual disease
effect of denosumab on cellular biomarkers in the human breast

Conditions: Healthy Volunteer, Female, Breast

Summary: to evaluate whether administration of denosumab results in a decrease compared to the control group in proliferation of mammary epithelial cells as measured by the ki-67 proliferation index.


Eligibility criteria:
inclusion criteria: * willing to use, in combination with her partner, 2 non-hormonal methods of effective contraception or practice sexual abstinence. subjects who are surgically sterile (eg, history of hysterectomy) or whose sexual partner is sterile (eg, history of vasectomy) are not required to use contraceptive measures * laboratory tests are within clinically acceptable range * clinically acceptable physical exam and no history or evidence of any clinically significant medical disorder that would pose a risk to subject safety or interfere with study evaluations or procedures. exclusion criteria: * female subject with a prior history of breast cancer; breast implant in the breast to be biopsied; known history of fibrocystic breast disease * subject is unable or unwilling to provide breast biopsy tissue from the upper outer quadrant of her breast * pregnant or plans to become pregnant while exposed to investigational product * lactating/breastfeeding or plans to breastfeed while exposed to investigational product * recent use of any non-approved medications or devices * uncontrolled thyroid disorder * significant dental/oral disease * planned invasive dental procedures * positive urine screen for alcohol and/or drugs
use of sildenafil for treatment of urinary incontinence

Conditions: Urinary Incontinence

Summary: the investigators goal is to develop medical treatments for stress/mixed urinary incontinence. sildenafil has been shown to improve blood flow as well as muscle mass and strength and to decrease muscle fatigue. the investigators believe that it will improve muscular atrophy in the pelvic floor, thus improving symptoms of urinary incontinence related to pelvic floor dysfunction.

aim: to determine the effect of sildenafil on urinary incontinence. 1. episodes of urinary incontinence will be recorded using a 3 day bladder diary. 2. quantitative assessment of urinary incontinence will be performed at baseline and after treatment using a pad test. 3. muscle strength will be assessed through use of a perineometer. 4. to evaluate macrocirculatory blood flow in pelvic organs, women will be assessed with noninvasive imaging before and after randomization to sildenafil. 5. secondary outcomes will include evaluation of muscle and vaginal mucosal thickness.

Eligibility criteria:
inclusion criteria: * postmenopausal females, 50-80 years of age, at the time of consent * have stress or mixed urinary incontinence, with at least 3 episodes/week * willing and able to comply with study procedures * willing and able to provide written informed consent exclusion criteria: * significant heart, liver, kidney, pulmonary, blood, autoimmune or peripheral vascular disease (history of hashimoto's thyroiditis is not exclusionary if stable and thyroid replacement is being administered. thyroid testing will be performed at screening and as needed during study visits. ) * systolic blood pressure \ 150, diastolic blood pressure \ 90 after repeated evaluation with proper cuff. this range is smaller than the acceptable range stated in the prescribing information for sildenafil (\>90/50 and \<170/110) * diabetes mellitus or other untreated endocrine disease * active cancer * currently using and planning to continue use of urinary incontinence medications during study period * bmi \> 40 * hiv, hepatitis b, or hepatitis c * use of systemic nitrates, anabolic steroids or corticosteroids in the past 6 months * use of alpha blockers * any medical condition that, in the opinion of the investigator, would place the subject at increased risk for participation. * known allergic reaction to any agent under investigation or required by the protocol. * history of prior non-compliance or the presence or history of psychiatric condition (including drug or alcohol addiction) that would, in the opinion of the investigator, make it difficult for the subject to comply with the study procedures or follow the investigators instructions. * females who are pregnant or lactating.

Keywords: urinary incontinence pelvic floor dysfunction
a 3-month study to compare the safety of ons-5010 in vials versus pre-filled syringe in subjects with visual impairment due to retinal disorders

Conditions: Age-Related Macular Degeneration; Neovascular Age-related Macular Degeneration; Wet Macular Degeneration; BRVO - Branch Retinal Vein Occlusion; Diabetic Macular Edema

Summary: the study will compare the safety of ophthalmic bevacizumab in vials versus pre-filled syringes in subjects diagnosed with a retinal condition that would benefit from treatment with intravitreal injection of bevacizumab, including: exudative age-related macular degeneration, diabetic macular edema, or branch retinal vein occlusion.


Eligibility criteria:
inclusion criteria: * active clinical diagnosis and oct confirmation of one of the following retinal disorders: exudative age-related macular degeneration (amd), diabetic macular edema (dme), or branch retinal vein occlusion (brvo) and, in the opinion of the investigator, requires treatment with an anti-vegf therapy exclusion criteria: * previous use of approved anti-vegf or avastin® within 4 weeks preceding randomization * previous use of beovu® * macular edema due to something other than exudative amd, dme or brvo, in the study eye * history of inadequate response to previous intravitreal anti-vegf therapy * history of any intraocular or periocular corticosteroid injection or implant, in the study eye * laser photocoagulation (juxtafoveal or extrafoveal) in the study eye within 1-month preceding randomization * any concurrent intraocular condition in the study eye that may require medical or surgical intervention or contribute to vision loss during the study period * active intraocular inflammation in the study eye * current vitreous hemorrhage in the study eye * polypoidal choroidal vasculopathy (pcv) in the study eye * history of idiopathic, infectious or autoimmune-associated uveitis in either eye * current ocular or periocular infection, such as conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye * uncontrolled glaucoma in the study eye (defined as intraocular pressure ≥30 mmhg despite treatment with anti-glaucoma medication) * premenopausal women not using adequate contraception * current treatment for active systemic infection * known allergy to any component of the study drug , not amenable to treatment
sleep related breathing disturbances and high altitude pulmonary hypertension in kyrgyz highlanders

Conditions: High Altitude Pulmonary Hypertension; Sleep Apnea

Summary: high altitude pulmonary hypertension, a form of altitude illness that occurs in long-term residents at altitudes \>2500 m, is characterized by dyspnea, hypoxemia, impaired exercise performance and hypertension in the pulmonary circulation. whether sleep related breathing disturbances, common causes of nocturnal hypoxemia in lowlanders, are also prevalent in highlanders and promote pulmonary hypertension in highlanders is unknown. therefore, the current study will investigate whether highlanders with high altitude pulmonary hypertension have a greater prevalence of sleep apnea than healthy highlanders and lowlanders.


Eligibility criteria:
inclusion criteria: * high altitude pulmonary hypertension confirmed by clinical presentation and systolic pulmonary artery pressure \>50 mmhg measured by echocardiography at altitude of residence. * healthy subjects (high altitude controls) * both genders * age \>16 y * kyrgyz ethnicity * born, raised and currently living at \>2500 m * healthy subjects currently living at \<1000 m (low altitude controls) exclusion criteria: * pulmonary hypertension from other causes, in particular from left ventricular failure as judged clinically and by echocardiography * excessive erythrocytosis * other coexistent disorders that may interfere with the cardio-respiratory system and sleep * regular use of medication that affects control of breathing * heavy smoking

Keywords: high altitude illness pulmonary hypertension sleep apnea hypoxia
gnrh antagonist for treatment of early ovarian hyperstimulation syndrome

Conditions: Ovarian Hyperstimulation Syndrome; Effects of Gonadotropin; Oocyte Maturation

Summary: the aim of this study is to analyze the effectiveness of gnrh antagonist in the treatment of early ovarian hyperstimulation syndrome.

ovarian hyperstimulation syndrome (ohss) is a serious complication of ovarian stimulation protocols. gonadotrophin-releasing hormone (gnrh) antagonist administration in the luteal phase was recently proposed as a new approach for the management of patients with established severe ohss we analyze the response of egg donors with moderate- severe early ovarian hyperstimulation syndrome after a gnrh antagonist stimulation protocol to the administration of a daily doses of gnrh antagonist (cetrorelix 0.25) during 7 days after the second day of oocyte retrieval compared with placebo (saline solution).

Eligibility criteria:
inclusion criteria: * egg donors * volunteers. * 18-35 years old * healthy * bmi \< 30 * ohhs after oocyte retrieval defined as ascitis \> 9 cm2 associate to abdominal pain, sickness, abdominal distention,or haematocrit (ht) \>45% an white blood cell count \>15,000/mm3 or creatine \> 1.2 mg/dl or transaminases \> 40 iu/liter exclusion criteria: * bmi \> 30 * allergy to gnrh antagonist

Keywords: ovarian hyperstimulation syndrome (ohss) gnrh antagonist ascitis.
contingency management for chronic recidivist alcohol-dependent patients

Conditions: Alcohol Dependence

Summary: the purpose of this study is to evaluate the efficacy of prize contingency management (cm) in reducing in-patient detoxification services for chronic recidivist alcohol-dependent patients.

this study evaluates the efficacy of prize contingency management (cm) in reducing in-patient detoxification services for chronic recidivist alcohol-dependent patients. 116 alcohol-dependent patients who have received 4 or more alcohol detoxifications in a calendar year will be randomly assigned to one of two 6-month treatment conditions: standard case management treatment, or standard case management treatment plus cm. in the cm condition, patients earn the chance to win prizes by submitting negative breath samples and by complying with steps toward treatment goals, such as attending outpatient substance abuse treatment services, attending appointments with low income housing programs, or complying with outpatient psychiatric treatment. treatment services received, alcohol and drug use, psychosocial functioning, and hiv risk behaviors will be measured pre-treatment and at months 1, 3, and 6 (post-treatment), and at follow-ups scheduled for 9, 12, and 18 months after intake.

Eligibility criteria:
inclusion criteria: * age 18 years or older * four or more inpatient alcohol detoxifications in the previous 12 months * current diagnosis of dsm-iv alcohol dependence exclusion criteria: -

Keywords: contingency management alcohol dependence
comparison of superficial+deep vs. deep serratus anterior plan block in video-assisted thoracic surgery

Conditions: Analgesia

Summary: thoracotomy is one of the most painful surgeries; video-assisted thoracoscopic surgery (vats) has been developed to reduce the surgical stress of thoracotomy. however, patients may experience moderate to severe pain within the first 24 hours after vats. intravenous opioids are frequently used to provide postoperative analgesia, and accordingly, side effects such as postoperative nausea/vomiting and respiratory depression can be seen. the aim of this study is to compare superficial+deep vs. deep serratus anterior plan block for postoperative pain control in vats cases.


Eligibility criteria:
inclusion criteria: 1. american society of anesthesiologist's physiologic state i-iii patients 2. to undergo video assisted thoracic surgery 3. being between the ages of 18-65 years exclusion criteria: * having a known heart, kidney, liver or hematological disease * having a history of peptic ulcer, gastrointestinal bleeding, allergy, chronic pain * routine analgesic use and history of analgesic use in the last 24 hours * not willingto participate in the study * uncooperative patients who have coagulopathy or use anticoagulant drugs * to be allergic to one of the drugs to be used * contraindication for video assisted thoracic surgery